Walgreens has received a U.S. patent for new proprietary technology that its Walgreens community specialty pharmacists and AllianceRx Walgreens Prime’s specialty pharmacists will use to facilitate communication with and counseling of patients prescribed oral oncology medicines. Through Walgreens Connected Care® Oncology, an evidence-based, patient-centered process focused on driving medication adherence and improving patient outcomes, this newly patented technology helps guide interactions with patients, helping them stay on their treatment and manage any possible side effects. Historically, chemotherapy and other cancer medicines have been administered under the direct supervision of a medical professional in an outpatient clinic or in-patient hospital. However, more recently medical science has created oral cancer medicines called oncolytics that patients can take from the comfort of their home. While oncolytics offer convenience, they are still powerful medicines designed to treat cancer in accordance with complex treatment plans that are critical to patient outcomes. The patented technology arms Walgreens and AllianceRx Walgreens Prime specialty pharmacy teams with a set of questions and informational scripts to guide conversations with Connected Care Oncology patients. Branching logic within the technology adapts the set of questions and informational scripts in real time. Each patient interaction is customized to focus on patient specific variables - including prescribed medication, adverse events and adherence - and provides the proper support to the patient based on their current situation.